CDKN2A and meningioma: A heterozygous deletion of cyclin-dependent kinase inhibitors A and B (CDKN2A/B) was also associated with a shorter time of meningioma recurrence, and it importantly correlates with shorter RFS in surgically resected atypical meningiomas [41,69].